Al-Waiz Makram M, Sharquie Khalifa E, A-Qaissi Mohammed H, Hayani Raafa K
Department of Dermatology and Venereology, College of Medicine, University of Baghdad, Medical City Teaching Hospital.
Dermatol Online J. 2005 Dec 1;11(3):3.
Behçet disease is a chronic relapsing disease characterized by multiple signs and symptoms such as recurrent orogenital ulceration, eye involvement, skin manifestations, and other systemic involvement. Multiple therapeutic modalities have been used to treat Behçet disease. These agents act through different mechanisms and are associated with a variety of side effects. We performed a case-comparative study to evaluate efficacy of combined colchicine and benzathine penicillin in the treatment and prophylaxis of Behçet disease. Sixty-six patients who fulfilled the international study group criteria for diagnosis of Behçet disease were included. The patients were divided into three groups: group 1 (20 patients) received 1.2 Mu benzathine penicillin injection monthly; group 2 (21 patients) received two tablets of colchicine daily (each tablet contained 0.5 mg); and group 3 (25 patients) received both 1.2 Mu benzathine penicillin injection monthly and two tablets of colchicine daily. Each patient was followed up monthly for 5 months, 4 months on treatment and 1 additional month followup. The clinical manifestation index (CMI), the numerical sum of the clinical features, was calculated for each patient initially and then monthly. Pathergy test was performed for each patient monthly. The CMI was reduced by colchicine and benzathine penicillin treatment, and the reduction was highly significant. The reduction in the CMI remains satisfactory and good for 1 month after stopping the treatment. When each colchicine and benzathine Penicillin are used alone the index is also reduced significantly, but this reduction is much less than when both drugs are used together and there is also rapid and earlier relapse. Based on our findings, the combination of colchicine and benzathine penicillin appears to be of greater efficacy in the treatment of Behçet disease than the use of either drug alone.
白塞病是一种慢性复发性疾病，其特征为多种体征和症状，如反复出现的口腔和生殖器溃疡、眼部受累、皮肤表现以及其他全身受累情况。多种治疗方式已被用于治疗白塞病。这些药物通过不同机制起作用，并伴有各种副作用。我们进行了一项病例对照研究，以评估秋水仙碱和苄星青霉素联合使用在白塞病治疗和预防中的疗效。纳入了66例符合国际研究组白塞病诊断标准的患者。患者被分为三组：第1组（20例患者）每月接受120万单位苄星青霉素注射；第2组（21例患者）每日服用两片秋水仙碱（每片含0.5毫克）；第3组（25例患者）每月接受120万单位苄星青霉素注射且每日服用两片秋水仙碱。每位患者每月随访5个月，治疗4个月，额外随访1个月。最初及随后每月为每位患者计算临床表现指数（CMI），即临床特征的数值总和。每月为每位患者进行针刺反应试验。秋水仙碱和苄星青霉素治疗使CMI降低，且降低非常显著。停药后1个月内CMI的降低仍保持令人满意且良好的状态。当单独使用秋水仙碱和苄星青霉素时，该指数也显著降低，但这种降低远小于两种药物联合使用时，且复发迅速且更早。基于我们的研究结果，秋水仙碱和苄星青霉素联合使用在治疗白塞病方面似乎比单独使用任何一种药物更有效。
